{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:21:48Z","timestamp":1787602908537,"version":"build-2736575974"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1762","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved olezarsen (Tryngolza \u2013 Ionis), a subcutaneously injected apolipoprotein C-III (apoC-III)-directed antisense oligonucleotide, to reduce triglyceride levels and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. Olezarsen and the apoC-III-directed small interfering RNA plozasiran (Redemplo) were approved earlier to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS).<\/jats:p>","DOI":"10.58347\/tml.2026.1762c","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:32:25Z","timestamp":1787599945000},"page":"141-143","source":"Crossref","is-referenced-by-count":0,"title":["Olezarsen (Tryngolza) for Severe Hypertriglyceridemia"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,8,31]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:32:25Z","timestamp":1787599945000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1762c"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":0,"journal-issue":{"issue":"1762","published-online":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1762c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}